Clinical and biochemical effects of the E139K missense mutation in the TIMP3 gene, associated with Sorsby fundus dystrophy

Purpose To determine the phenotypic and biochemical characteristics of the p.E139K missense variant in tissue inhibitor of metalloproteinase 3 (TIMP3) associated with Sorsby fundus dystrophy (SFD). Methods The coding regions and adjacent intronic sequence of TIMP3 were amplified by polymerase chain reaction and then analyzed by bidirectional sequencing. Allele-specific PCR was used to determine the minimum allele frequency of the mutant allele in ethnically matched controls. Clinical examination and imaging of affected individuals with color fundus photography, scanning laser ophthalmoscope (fundal autofluorescence), and optical coherence tomography was performed. A mutant construct of the TIMP3 protein was created and expressed in human retinal pigment epithelium (ARPE19) cells, which were then assayed for oligomerization and intrinsic matrix metalloproteinase (MMP) inhibitory activity. Results Three affected individuals from a family of Welsh origin each harbored one allele of the TIMP3 missense variant c.415 G>A, (p.E139K), which was not identified in 534 ethnically matched control chromosomes and thus presumed pathogenic. The mutant protein was shown to dimerize in culture cells and retain its MMP inhibitory activity. Retinal examination was variable between eyes of affected individuals and between family members. Drusen-like deposits were common to all three affected individuals and yellow subretinal deposits, exudative maculopathy, and geographic atrophy were also observed. Optical coherence tomography (OCT) images of affected individuals demonstrated hyperreflectivity of the RPE-photoreceptor-choroid complex. Conclusions The TIMP3 p.E139K mutation is another cause of SFD. It is the second TIMP3 sequence variant reported that does not affect the number of cysteine residues in the mutant protein yet dimerizes in vitro. The clinical presentation of this family is in keeping with previous clinical reports of this disorder.

[1]  S. Gallati,et al.  Novel TIMP3 Mutation (Glu139Lys) in a Large Swiss Pedigree With Sorsby Fundus Dystrophy , 2007 .

[2]  M. Blumenkranz,et al.  A novel His158Arg mutation in TIMP3 causes a late-onset form of Sorsby fundus dystrophy. , 2006, American journal of ophthalmology.

[3]  M. Young,et al.  Optical coherence tomography for assessing disease progression in sorsby fundus dystrophy. , 2006, Retina.

[4]  A. Webster,et al.  A Novel TIMP3 Mutation and in vivo Imaging of a Family With Sorsby Fundus Dystrophy , 2006 .

[5]  N. Brown,et al.  Sorsby's fundus dystrophy mutations impair turnover of TIMP-3 by retinal pigment epithelial cells. , 2005, Human molecular genetics.

[6]  M. Clarke,et al.  TIMP3 mutation in Sorsby's fundus dystrophy: molecular insights , 2005, Expert Reviews in Molecular Medicine.

[7]  L. Yannuzzi,et al.  A novel TIMP3 mutation associated with Sorsby fundus dystrophy. , 2005, Archives of ophthalmology.

[8]  H. Schrewe,et al.  Sorsby fundus dystrophy mutation Timp3S156C affects the morphological and biochemical phenotype but not metalloproteinase homeostasis , 2003, Journal of cellular physiology.

[9]  C. E. Arris,et al.  Expression of mutant and wild-type TIMP3 in primary gingival fibroblasts from Sorsby's fundus dystrophy patients. , 2003, Biochimica et biophysica acta.

[10]  C. Grimm,et al.  A mouse model for Sorsby fundus dystrophy. , 2002, Investigative ophthalmology & visual science.

[11]  K. Yeow,et al.  Expression of Sorsby's Fundus Dystrophy Mutations in Human Retinal Pigment Epithelial Cells Reduces Matrix Metalloproteinase Inhibition and May Promote Angiogenesis* , 2002, The Journal of Biological Chemistry.

[12]  V. Sheffield,et al.  Novel mutation in the TIMP3 gene causes Sorsby fundus dystrophy. , 2002, Archives of ophthalmology.

[13]  G. Murphy,et al.  Full-length and N-TIMP-3 display equal inhibitory activities toward TNF-alpha convertase. , 2001, Biochemical and biophysical research communications.

[14]  V. Knäuper,et al.  Localization of the Death Domain of Tissue Inhibitor of Metalloproteinase-3 to the N Terminus , 2000, The Journal of Biological Chemistry.

[15]  J. Goodship,et al.  A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in Sorsby's fundus dystrophy. , 2000, The Journal of biological chemistry.

[16]  A. Bird,et al.  TIMP-3, collagen, and elastin immunohistochemistry and histopathology of Sorsby's fundus dystrophy. , 2000, Investigative ophthalmology & visual science.

[17]  A. Milam,et al.  Accumulation of tissue inhibitor of metalloproteinases-3 in human eyes with Sorsby’s fundus dystrophy or retinitis pigmentosa , 1998, The British journal of ophthalmology.

[18]  N. Ohba,et al.  A novel splice site mutation in the tissue inhibitor of the metalloproteinases-3 gene in Sorsby’s fundus dystrophy with unusual clinical features , 1998, Human Genetics.

[19]  M. Barker,et al.  Localization of the Functional Domains of Human Tissue Inhibitor of Metalloproteinases-3 and the Effects of a Sorsby’s Fundus Dystrophy Mutation* , 1998, The Journal of Biological Chemistry.

[20]  U. Felbor,et al.  Sorsby fundus dystrophy: reevaluation of variable expressivity in patients carrying a TIMP3 founder mutation. , 1997, Archives of ophthalmology.

[21]  Y. Shi,et al.  Computational Sequence Analysis of the Tissue Inhibitor of Metalloproteinase Family , 1997, Journal of protein chemistry.

[22]  P. Campochiaro,et al.  Localization of TIMP-3 mRNA expression to the retinal pigment epithelium. , 1996, Investigative ophthalmology & visual science.

[23]  H. Stöhr,et al.  A novel Ser156Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby's fundus dystrophy with unusual clinical features. , 1995, Human molecular genetics.

[24]  V. Sheffield,et al.  Night blindness in Sorsby's fundus dystrophy reversed by vitamin A , 1995, Nature Genetics.

[25]  R. Pruett,et al.  Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy , 1994, Nature Genetics.

[26]  C. M. Kemp,et al.  Abnormal dark adaptation and rhodopsin kinetics in Sorsby's fundus dystrophy. , 1992, Investigative ophthalmology & visual science.

[27]  H. Morris,et al.  Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). , 1990, The Biochemical journal.

[28]  A. Bird,et al.  Sorsby's fundus dystrophy. A light and electron microscopic study. , 1989, Ophthalmology.

[29]  A. Bird,et al.  Sorsby's fundus dystrophy. A clinical study. , 1989, Ophthalmology.

[30]  W. K. Hamilton,et al.  Sorsby's fundus dystrophy. , 1989, Ophthalmology.

[31]  H. Alanko,et al.  Pseudoinflammatory fundus dystrophy with autosomal recessive inheritance. , 1982, American journal of ophthalmology.

[32]  K. Yeow,et al.  Sorsby's fundus dystrophy tissue inhibitor of metalloproteinases-3 (TIMP-3) mutants have unimpaired matrix metalloproteinase inhibitory activities, but affect cell adhesion to the extracellular matrix. , 2002, Matrix biology : journal of the International Society for Matrix Biology.

[33]  J. Gibson,et al.  Sorsby's fundus dystrophy: A case report of 24 years follow-up with electrodiagnostic tests and indocyanine green angiography , 1999, Eye.

[34]  D. Denhardt,et al.  Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. , 1993, Pharmacology & therapeutics.

[35]  A. Sorsby,et al.  A fundus dystrophy with unusual features. , 1949, The British journal of ophthalmology.